A
Anna Gahlen
Researcher at Ruhr University Bochum
Publications - 11
Citations - 756
Anna Gahlen is an academic researcher from Ruhr University Bochum. The author has contributed to research in topics: Neuromyelitis optica & Optic neuritis. The author has an hindex of 5, co-authored 11 publications receiving 486 citations.
Papers
More filters
Journal ArticleDOI
Neuromyelitis optica: Evaluation of 871 attacks and 1,153 treatment courses.
Ingo Kleiter,Anna Gahlen,Nadja Borisow,Katrin Fischer,Klaus-Dieter Wernecke,Brigitte Wegner,Kerstin Hellwig,Florence Pache,Klemens Ruprecht,Joachim Havla,Markus Krumbholz,Tania Kümpfel,Orhan Aktas,Hans-Peter Hartung,Marius Ringelstein,Christian Geis,Christoph Kleinschnitz,Achim Berthele,Bernhard Hemmer,Klemens Angstwurm,Jan-Patrick Stellmann,Simon Schuster,Martin Stangel,Florian Lauda,Hayrettin Tumani,Christoph Mayer,Lena Zeltner,Ulf Ziemann,Ralf A. Linker,Matthias Schwab,Martin Marziniak,Florian Then Bergh,Ulrich Hofstadt-van Oy,Oliver Neuhaus,Alexander Winkelmann,Wael Marouf,Jürgen H. Faiss,Brigitte Wildemann,Friedemann Paul,Sven Jarius,Corinna Trebst +40 more
TL;DR: The frequency, sequence, and efficacy of therapies used for NMO attacks are analyzed and it is shown that certain therapies are more effective than others in cases of severe N MO attacks.
Journal ArticleDOI
Apheresis therapies for NMOSD attacks: A retrospective study of 207 therapeutic interventions
Ingo Kleiter,Anna Gahlen,Nadja Borisow,Katrin Fischer,Klaus-Dieter Wernecke,Kerstin Hellwig,Florence Pache,Klemens Ruprecht,Joachim Havla,Tania Kümpfel,Orhan Aktas,Hans-Peter Hartung,Marius Ringelstein,Christian Geis,Christoph Kleinschnitz,A. Berthele,Bernhard Hemmer,Klemens Angstwurm,Jan-Patrick Stellmann,Simon Schuster,Martin Stangel,Florian Lauda,Hayrettin Tumani,Christoph Mayer,Markus Krumbholz,Lena Zeltner,Ulf Ziemann,Ralf A. Linker,Matthias Schwab,Martin Marziniak,Florian Then Bergh,Ulrich Hofstadt-van Oy,Oliver Neuhaus,Uwe K. Zettl,Jürgen H. Faiss,Brigitte Wildemann,Friedemann Paul,Sven Jarius,Corinna Trebst +38 more
TL;DR: Early use of an apheresis therapy in NMOSD attacks, particularly in AQP4-ab-seropositive patients is suggested, as Class IV evidence that for patients withNMOSD, neither PE nor IA is superior in the treatment of attacks is provided.
Journal ArticleDOI
Immunotherapies in neuromyelitis optica spectrum disorder: efficacy and predictors of response
Jan-Patrick Stellmann,Markus Krumbholz,Tim Friede,Anna Gahlen,Nadja Borisow,Katrin Fischer,Kerstin Hellwig,Florence Pache,Klemens Ruprecht,Joachim Havla,Tania Kümpfel,Orhan Aktas,Hans-Peter Hartung,Marius Ringelstein,Christian Geis,Christoph Kleinschnitz,Achim Berthele,Bernhard Hemmer,Klemens Angstwurm,Kim Lea Young,Simon Schuster,Martin Stangel,Florian Lauda,Hayrettin Tumani,Christoph Mayer,Lena Zeltner,Ulf Ziemann,Ralf A. Linker,Matthias Schwab,Martin Marziniak,Florian Then Bergh,Ulrich Hofstadt-van Oy,Oliver Neuhaus,Uwe K. Zettl,Jürgen H. Faiss,Brigitte Wildemann,Friedemann Paul,Sven Jarius,Corinna Trebst,Ingo Kleiter +39 more
TL;DR: Age, antibody status and possibly previous attacks predict further attacks in patients treated for NMOSD, and azathioprine and rituximab are superior to interferon-β.
Journal ArticleDOI
Influence of female sex and fertile age on neuromyelitis optica spectrum disorders
Nadja Borisow,Ingo Kleiter,Anna Gahlen,Katrin Fischer,Klaus-Dieter Wernecke,Florence Pache,Klemens Ruprecht,Joachim Havla,Markus Krumbholz,Tania Kümpfel,Orhan Aktas,Marius Ringelstein,Christian Geis,Christoph Kleinschnitz,Achim Berthele,Bernhard Hemmer,Klemens Angstwurm,Robert Weissert,Jan-Patrick Stellmann,Simon Schuster,Martin Stangel,Florian Lauda,Hayrettin Tumani,Christoph Mayer,Lena Zeltner,Ulf Ziemann,Ralf A. Linker,Matthias Schwab,Martin Marziniak,Florian Then Bergh,Ulrich Hofstadt-van Oy,Oliver Neuhaus,Alexander Winkelmann,Wael Marouf,Lioba Rückriem,Jürgen H. Faiss,Brigitte Wildemann,Friedemann Paul,Sven Jarius,Corinna Trebst,Kerstin Hellwig,Nemos +41 more
TL;DR: The data suggest an influence of sex and age on susceptibility to AQP4-ab-positive NMO/SD, and genetic and hormonal factors might contribute to pathophysiology of N MO/SD.
Journal ArticleDOI
Interleukin-6 Receptor Blockade in Treatment-Refractory MOG-IgG-Associated Disease and Neuromyelitis Optica Spectrum Disorders.
Marius Ringelstein,Ilya Ayzenberg,Gero Lindenblatt,Katinka Fischer,Anna Gahlen,Giovanni Novi,Helen K Hayward-Könnecke,Sven Schippling,Paulus S. Rommer,Barbara Kornek,Tobias Zrzavy,Damien Biotti,Jonathan Ciron,Bertrand Audoin,Achim Berthele,Katrin Giglhuber,Hélène Zéphir,Tania Kümpfel,Robert Berger,Joachim Röther,Vivien Häußler,Jan-Patrick Stellmann,Daniel Whittam,Anu Jacob,Markus Kraemer,Antoine Gueguen,Romain Deschamps,Antonios Bayas,Martin W. Hümmert,Corinna Trebst,Axel Haarmann,Sven Jarius,Brigitte Wildemann,Matthias Grothe,Nadja Siebert,Klemens Ruprecht,Friedemann Paul,Nicolas Collongues,Romain Marignier,Michael J. Levy,Michael Karenfort,Michael Deppe,Philipp Albrecht,Kerstin Hellwig,Ralf Gold,Hans-Peter Hartung,Sven G. Meuth,Ingo Kleiter,Orhan Aktas +48 more
TL;DR: In this article, the authors evaluated the long-term safety and efficacy of TCZ, a humanized anti-interleukin-6 receptor antibody in myelin oligodendrocyte glycoprotein-IgG-associated disease (MOGAD) and neuromyelitis optica spectrum disorders (NMOSD).